ADIA to Invest USD 200 Million in Meril
Founded by the Bilakhia Group, Meril is a global innovator in medical technology (MedTech), with a strong focus on clinically advanced solutions across multiple specialties — including Cardiovascular, Structural Heart, Orthopaedics, Endo-surgery, In-vitro Diagnostics and Surgical Robotics.
Headquartered in Vapi, India, Meril operates state-of-the-art, vertically integrated, and globally certified manufacturing and R&D facilities, across a 100-acre sustainable MedTech campus. The company employs more than 13,000 people, has 35+ global subsidiaries, and serves healthcare systems in 150+ countries. Meril is committed to becoming the world's leading MedTech company, powered 100% by green energy, reinforcing its commitment to sustainable innovation.
With a robust in-house global R&D ecosystem and a portfolio of 200+ technology platforms, Meril continues to lead in global clinical research and education. Breakthrough innovations such as the Myval Transcatheter Heart Valve (THV) series, MyClip Transcatheter Edge-to-Edge Repair (TEER) system, and the MISSO Surgical Robotic System highlight Meril's dedication to next-generation innovation. Through its 12+ global training academies, Meril empowers over 10,000 healthcare professionals annually.
Sanjeev Bhatt, Senior Vice President – Strategy, Meril said: 'This investment by ADIA reinforces confidence in Meril's long term vision and global ambitions. This investment will enable us to accelerate growth, attract world-class talent, and further strengthen our RCD and clinical research efforts as we work towards improving the quality of human life through advanced healthcare solutions.'
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Hindu
8 minutes ago
- The Hindu
Rupee falls for sixth straight session, ends 3 paise lower against U.S. dollar
The rupee stayed weak for the sixth consecutive session and settled with a loss of 3 paise at 86.41 (provisional) against the dollar on Wednesday (July 23, 2025), amid a strong American currency and outflow of foreign funds. Forex traders said the domestic unit, however, found some cushion due to lower crude oil prices and heavy buying in domestic equity markets in line with global trends after the U.S. announced a trade deal with Japan. At the interbank foreign exchange, the Indian currency opened weak at 86.46 and touched the intra-day peak of 86.34 against the greenback. The unit ended the session at 86.41 (provisional), registering a loss of 3 paise from its previous closing level. At the end of Tuesday's (July 22) trading session, the local unit settled at 86.38, down 7 paise over its previous close. This was rupee's fifth straight session of decline since July 16 when the unit had lost 16 paise and settled at 85.92 against the dollar. Decline in crude oil prices offsets FIIs' outflows Anuj Choudhary, Research Analyst at Mirae Asset Sharekhan, said the rupee weakened on a strong greenback and foreign institutional investors' outflows. However, overnight decline in crude oil prices and positive domestic equities cushioned the downside. "Traders may take cues from PPI and industrial production data from the US. USD-INR spot price is expected to trade in a range of ₹85.60 to ₹86.30," he added. The dollar index, which gauges the greenback's strength against a basket of six currencies, rose 0.04 per cent to 97.16. Analysts attributed gains in dollar index to higher inflation in the U.S. that has reduced hopes for an interest rate cut by the Federal Reserve. Brent crude, the global oil benchmark, declined 0.52 per cent to USD 68.23 per barrel in futures trade. According to experts, investors are awaiting the outcome of India-U.S. trade talks ahead of the August 1 deadline as Indian exporters are staring at higher tariffs in American market. If the discussions fail or get delayed, Indian exporters could face fresh pressure — adding to the rupee's challenges. The U.S. team will visit India in August for the next round of negotiations for the proposed bilateral trade agreement between the two countries. India and the U.S. teams concluded the fifth round of talks for the agreement last week in Washington. Meanwhile, in the domestic equity market, Sensex climbed 539.83 points, or 0.66 per cent, to 82,726.64, while Nifty rose 159.00 points, or 0.63 per cent, to 25,219.90. Foreign institutional investors (FIIs) offloaded equities worth ₹3,548.92 crore on a net basis on Tuesday (July 22), according to exchange data.
Time of India
18 minutes ago
- Time of India
Natco Pharma offers to acquire nearly 36% stake in Adcock Ingram in Rs 2,100-cr deal
Natco Pharma on Wednesday said it has offered to acquire nearly 36 per cent stake in South African drug firm Adcock Ingram Holdings for up to Rs 2,100 crore in a cash deal. The Hyderabad-based firm said it has submitted a firm intention offer to Adcock Ingram Holdings to buy out minority shareholders for a cash offer of R75 (USD 4.271) per share. Explore courses from Top Institutes in Please select course: Select a Course Category Artificial Intelligence Leadership Public Policy others Healthcare Degree Data Science Data Analytics Others MCA healthcare Design Thinking CXO Technology Operations Management PGDM MBA Management Finance Product Management Project Management Data Science Digital Marketing Cybersecurity Skills you'll gain: Duration: 7 Months S P Jain Institute of Management and Research CERT-SPJIMR Exec Cert Prog in AI for Biz India Starts on undefined Get Details Should the offer be accepted, the company will hold a 35.75 per cent stake in Adcock Ingram, valued at R4 billion (USD 226 million), it stated in a regulatory filing. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Struggling With Belly Fat? Try This at Home Home Fitness Hack Shop Now Undo The acquisition amounts to 51,643,319 equity shares resulting in Natco shareholding to arrive at 35.75 per cent of the paid-up equity share capital in aggregate, it said. Adcock Ingram is estimated at a valuation of R11 billion (USD 632 million). Live Events It is envisaged that post-acquisition, Adcock will continue to operate as a private South African business, supported by two substantial strategic shareholders, Bidvest at 64.25 per cent and Natco at 35.75 per cent, including a prior held stake, the company stated. Natco currently holds 0.80 per cent in Adcock Ingram. "The proposed transaction will provide NATCO Pharma with a well-established entry into the Southern African market. It will also allow NATCO Pharma to tap into new revenue streams and expand our footprint in one of the largest and growing emerging markets , while providing a gateway to the African continent," Natco Pharma CEO & Vice Chairman Rajeev Nannapaneni said. Adcock Ingram generated a revenue of R9.6 billion (USD 536 million) in the last financial year and delivered a gross margin of 33.4 per cent. "This is a significant moment in our company's long history. This offer represents a huge vote of confidence in Adcock Ingram's people, brands and business model, and the South African healthcare environment," Andrew Hall, CEO, Adcock Ingram Holdings, stated. Adcock Ingram will benefit from a partnership with a research-focused, innovative and vertically integrated pharmaceutical company, and over time South Africans will be beneficiaries of wider access to affordable medicines , he added. In addition, the offer represents an attractive premium for the minority shareholders, who have supported company over the years, he said. The estimated transaction completion time is four months, assuming no regulatory delays, Natco Pharma said. Business operations will remain uninterrupted, with no changes to existing partnerships, joint ventures, or supplier relationships, it noted. Natco Pharma shares ended 1.99 per cent up at Rs 1,034.50 apiece on BSE.
News18
an hour ago
- News18
Natco offers to acquire nearly 36 pc stake in Adcock Ingram in Rs 2,100-cr deal
New Delhi, Jul 23 (PTI) Natco Pharma on Wednesday said it has offered to acquire nearly 36 per cent stake in South African drug firm Adcock Ingram Holdings for up to Rs 2,100 crore in a cash deal. The Hyderabad-based firm said it has submitted a firm intention offer to Adcock Ingram Holdings to buy out minority shareholders for a cash offer of R75 (USD 4.271) per share. Should the offer be accepted, the company will hold a 35.75 per cent stake in Adcock Ingram, valued at R4 billion (USD 226 million), it stated in a regulatory filing. The acquisition amounts to 51,643,319 equity shares resulting in Natco shareholding to arrive at 35.75 per cent of the paid-up equity share capital in aggregate, it said. Adcock Ingram is estimated at a valuation of R11 billion (USD 632 million). It is envisaged that post-acquisition, Adcock will continue to operate as a private South African business, supported by two substantial strategic shareholders, Bidvest at 64.25 per cent and Natco at 35.75 per cent, including a prior held stake, the company stated. Natco currently holds 0.80 per cent in Adcock Ingram. 'The proposed transaction will provide NATCO Pharma with a well-established entry into the Southern African market. It will also allow NATCO Pharma to tap into new revenue streams and expand our footprint in one of the largest and growing emerging markets, while providing a gateway to the African continent," Natco Pharma CEO & Vice Chairman Rajeev Nannapaneni said. Adcock Ingram generated a revenue of R9.6 billion (USD 536 million) in the last financial year and delivered a gross margin of 33.4 per cent. 'This is a significant moment in our company's long history. This offer represents a huge vote of confidence in Adcock Ingram's people, brands and business model, and the South African healthcare environment," Andrew Hall, CEO, Adcock Ingram Holdings, stated. Adcock Ingram will benefit from a partnership with a research-focused, innovative and vertically integrated pharmaceutical company, and over time South Africans will be beneficiaries of wider access to affordable medicines, he added. In addition, the offer represents an attractive premium for the minority shareholders, who have supported company over the years, he said. The estimated transaction completion time is four months, assuming no regulatory delays, Natco Pharma said. Business operations will remain uninterrupted, with no changes to existing partnerships, joint ventures, or supplier relationships, it noted. Natco Pharma shares ended 1.99 per cent up at Rs 1,034.50 apiece on BSE. PTI MSS HVA view comments First Published: July 23, 2025, 17:30 IST Disclaimer: Comments reflect users' views, not News18's. Please keep discussions respectful and constructive. Abusive, defamatory, or illegal comments will be removed. News18 may disable any comment at its discretion. By posting, you agree to our Terms of Use and Privacy Policy.
